Additional file 3 of Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

Additional file 3: Supplemental Figure S2. Correlation between the observed response of breast cancer cell lines (N = 36) to neratinib and the response predicted by expression of (A) novel (N = 20) and (B) established (Desmedt et al [31], N = 24) gene panels. Plots were generated using CellMinerCDB online portal and cell line data from the BROAD Institute [34, 35].